Small cell lung cancer responds to immunogenic chemotherapy followed by PD-1 blockade.
Guido KroemerOliver KeppPublished in: Oncoimmunology (2021)
Sequential combination of immunogenic cell death (ICD)-induced interventions with subsequent immunotherapy has shown efficacy in preclinical models and clinical evaluation. Recently, a clinical trial enrolling small cell lung cancer patients treated with amrubicin together with PD-1 blockade confirmed the notion that ICD sensitizes tumors to immune checkpoint inhibitors.
Keyphrases
- small cell lung cancer
- clinical evaluation
- cell death
- clinical trial
- brain metastases
- diabetic rats
- high glucose
- physical activity
- drug induced
- cell therapy
- open label
- locally advanced
- oxidative stress
- cell cycle arrest
- randomized controlled trial
- radiation therapy
- stem cells
- study protocol
- cell proliferation
- endothelial cells